TNFSF4 and B-cell chronic lymphocytic leukemia: Interestingly, the preclinical use of genetically modified CD40L-expressing CLL cells in combination with IL-2- or OX40L-expressing CLL cells has shown to produce an even more pronounced T-cell activation and trigger therapeutically significant leukemia-specific immune responses (243, 244).